// App-Quantinova.ai

AB0310 (2021) : TOLERABILITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME, PRELIMINARY RESULTS

Researchers

Presenter

  • G. Tarasova

Principal Investigators

  • B. Belov

  • M. Cherkasova

  • E. Aseeva

  • T. Reshetnyak

  • N. Kosheleva

  • T. Popkova

Medical Centers

  • V.A. Nasonova Research Institute of Rheumatology, Laboratory for the Study of Comorbid Infections and Safety Control of Drug Therapy, Moscow, Russian Federation

  • V.A.Nasonova Research Institute of Rheumatology, Laboratory of Immunology and Molecular Biology of Rheumatic Diseases, Moscow, Russian Federation

  • V.A. Nasonova Research Institute of Rheumatology, Vascular Disease Laboratory, Moscow, Russian Federation

  • V.A. Nasonova Research Institute of Rheumatology, Vascular Disease Laboratory, Moscow, Russian Federation

  • V.A. Nasonova Research Institute of Rheumatology, Vascular Disease Laboratory, Moscow, Russian Federation

Locations

  • Russia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

  • Antiphospholipid syndrome

Biomarkers

  • BLM helicase

Drug/Treatment

  • Mycophenolate mofetil

  • CKD-4101

  • Pneumococcal polysaccharide vaccine

  • Hydroxychloroquine

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Glucocorticoid

  • Mycophenolic acid

  • Oraprine

  • Prednisone

  • Belimumab

  • Rituximab

  • PPV-23

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved